Saturday 17 October 2026
Export BMRA’s income statement to Excel — free account
Biomerica, Inc.
BMRA Healthcare Medical Devices
Biomerica, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $4.5 million, down 16.2% from fiscal 2025. In the quarter to May 2026, revenue grew 17.0%, EPS grew 37.8% and free cash flow fell 35.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
1.85
0.03
−1.60%
Follow BMRA
| May '17 | May '18 | May '19 | May '20 | May '21 | May '22 | May '23 | May '24 | May '25 | May '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 2 | 4 | 2 | 5 | 3 | 5 | 3 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
20.64 | 19.68 | 4.82 | 11.87 | 5.78 | 5.54 | (0.21) | (6.06) | (11.56) | (12.45) |
P/S ratio |
3.60 | 6.27 | 3.99 | 9.65 | 6.05 | 2.35 | 3.63 | 1.80 | 1.47 | 1.54 |
Altman Z″-Score (non-manufacturers) |
2.23 | (3.07) | (7.92) | 4.52 | (4.55) | (5.59) | (3.45) | (15.08) | (29.16) | (30.60) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(2.70) | (3.20) | (1.80) | (1.42) | (1.40) | (4.00) | (1.59) | (2.71) | (3.50) | (2.06) |
P/Operating CF |
(62.44) | (108.33) | (21.02) | (18.47) | (43.21) | (10.42) | (20.14) | (9.35) | (11.76) | (7.54) |
P/B ratio |
4.64 | 8.06 | 5.21 | 4.55 | 4.72 | 5.33 | 1.65 | 1.48 | 1.90 | 2.62 |
Price to Tangible BV |
4.83 | 8.25 | 5.35 | 4.61 | 4.87 | 5.44 | 1.68 | 1.53 | 2.01 | 2.84 |
EV/Sales |
3.38 | 6.05 | 3.85 | 8.35 | 5.46 | 2.04 | 1.81 | 1.03 | 1.01 | 1.25 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(27.11) | (28.68) | (8.93) | (13.01) | (7.49) | (80.25) | (1.77) | (1.04) | (1.40) | (1.63) |
EV/FCF |
(23.21) | (25.74) | (8.30) | (12.66) | (7.09) | (59.23) | (1.73) | (1.02) | (1.37) | (1.60) |
Quick Ratio |
4.32 | 2.24 | 1.69 | 7.05 | 4.35 | 3.33 | 5.37 | 2.32 | 1.80 | 0.84 |
Current Ratio |
7.96 | 5.00 | 3.56 | 10.00 | 7.10 | 4.69 | 6.58 | 3.51 | 2.80 | 1.62 |
Net Debt/EBITDA |
1.67 | 0.93 | 0.31 | 3.69 | 0.59 | 1.50 | 1.41 | 0.70 | 0.51 | 0.27 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
1.08 | 1.09 | 0.99 | 0.59 | 0.50 | 1.63 | 0.41 | 0.46 | 0.70 | 0.70 |
Operating CF/Net income |
0.80 | 0.80 | 0.94 | 1.61 | 0.71 | 0.11 | 0.77 | 0.90 | 0.77 | 0.91 |
Capex/Depreciation |
(0.44) | (0.70) | (1.05) | (0.30) | (0.79) | (0.29) | (0.22) | (0.31) | (0.09) | 0.00 |
Interest Coverage |
(3,182.00) | — | — | — | (18,749.25) | (170.45) | (54.31) | — | — | — |
| (18.72%) | (33.26%) | (57.62%) | (29.47%) | (63.60%) | (51.63%) | (71.23%) | (65.28%) | (92.99%) | (112.10%) | |
| (16.91%) | (28.63%) | (45.72%) | (23.79%) | (51.21%) | (39.07%) | (55.29%) | (50.43%) | (65.44%) | (59.43%) | |
ROIC |
(18.28%) | (29.67%) | (45.78%) | (30.74%) | (93.23%) | (117.68%) | (225.16%) | (164.37%) | (188.20%) | (251.51%) |
Return on Tangible Assets |
(22.64%) | (37.22%) | (66.82%) | (19.73%) | (90.35%) | (59.38%) | (64.53%) | (104.36%) | (152.08%) | (234.04%) |
Average Days of Receivables |
66.80 | 52.47 | 102.10 | 96.31 | 73.78 | 14.97 | 49.36 | 63.83 | 50.24 | 64.34 |
Research and Development Expense of Revenue |
19.52% | 25.13% | 32.29% | 28.88% | 30.48% | 9.60% | 29.67% | 27.53% | 19.26% | 17.70% |
Selling, General and Administrative Expense of Revenue |
31.87% | 33.03% | 38.95% | 38.05% | 78.78% | 30.20% | 113.97% | 101.33% | 86.84% | 109.90% |
Intangible Assets out of Total Assets |
0.03 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.04 | 0.03 |
Share Based Compensation of Revenue |
0.37% | 0.33% | 2.91% | 8.05% | 18.82% | 6.68% | 22.20% | 15.46% | 8.66% | 10.69% |
Graham Net Nets |
0.18 | 0.10 | 0.16 | 0.18 | 0.15 | 0.14 | 0.52 | 0.52 | 0.39 | (0.02) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(4.27%) | (4.18%) | (11.11%) | (4.16%) | (14.79%) | (10.29%) | (36.50%) | (62.07%) | (65.20%) | (53.78%) |
Free Cash Flow Yield |
(4.05%) | (3.75%) | (11.65%) | (6.84%) | (12.74%) | (1.46%) | (28.84%) | (56.11%) | (50.47%) | (50.54%) |
Revenue per Share |
5.56 | 5.19 | 4.52 | 5.27 | 4.83 | 11.91 | 3.02 | 2.57 | 2.31 | 1.53 |
Operating CF per Share |
(0.69) | (1.10) | (1.95) | (3.38) | (3.52) | (0.30) | (3.09) | (2.55) | (1.67) | (1.17) |
Capex per Share |
(0.09) | (0.12) | (0.15) | (0.09) | (0.20) | (0.11) | (0.04) | (0.05) | (0.02) | 0.00 |
Free Cash Flow per Share |
(0.79) | (1.22) | (2.10) | (3.48) | (3.72) | (0.41) | (3.14) | (2.60) | (1.69) | (1.17) |
Cash per Share |
1.18 | 1.12 | 0.60 | 6.80 | 2.82 | 3.74 | 5.49 | 1.98 | 1.04 | 0.45 |
Shareholders Equity per Share |
4.31 | 4.04 | 3.46 | 11.18 | 6.19 | 5.26 | 6.63 | 3.13 | 1.79 | 0.90 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.31 | 4.04 | 3.46 | 11.18 | 6.19 | 5.26 | 6.63 | 3.13 | 1.79 | 0.90 |
Free Cash Flow |
(0.82) | (1.30) | (2.42) | (4.42) | (5.55) | (0.65) | (5.55) | (5.48) | (3.88) | (3.42) |
Working Capital |
3.68 | 3.59 | 3.23 | 13.29 | 7.93 | 7.42 | 10.85 | 5.53 | 3.14 | 1.54 |
Capital Expenditures |
(0.10) | (0.13) | (0.17) | (0.12) | (0.30) | (0.17) | (0.08) | (0.11) | (0.04) | 0.00 |
Net Current Asset Value |
3.68 | 3.59 | 3.23 | 11.72 | 6.64 | 6.38 | 10.07 | 5.07 | 3.04 | (0.11) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.02 | 0.04 | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.66 | 0.53 | 0.46 | 1.43 | 1.21 | 2.78 | 1.65 | 1.86 | 2.96 | 5.40 |
Cash ROIC |
(14.33%) | (23.59%) | (51.74%) | (19.32%) | (41.32%) | (4.56%) | (25.89%) | (50.89%) | (59.64%) | (86.90%) |
Accounts Receivable Turnover |
5.71 | 5.98 | 4.61 | 4.16 | 4.47 | 16.93 | 7.14 | 6.49 | 6.33 | 5.87 |
Accounts Payable Turnover |
11.00 | 7.33 | 4.53 | 4.90 | 8.70 | 20.44 | 5.25 | 4.73 | 5.32 | 4.44 |
Inventory Turnover |
2.10 | 1.95 | 1.81 | 1.98 | 2.26 | 5.65 | 2.19 | 2.17 | 2.49 | 2.56 |
Average Days of Payables |
34.08 | 65.82 | 96.89 | 72.69 | 31.17 | 22.32 | 66.54 | 86.46 | 50.96 | 104.48 |
Days of Inventory on Hand |
167.41 | 208.74 | 200.87 | 210.02 | 171.28 | 55.48 | 153.37 | 180.52 | 113.00 | 152.30 |
Average Receivables |
1.01 | 0.93 | 1.13 | 1.61 | 1.61 | 1.11 | 0.75 | 0.83 | 0.84 | 0.76 |
Average Payables |
0.34 | 0.52 | 0.86 | 1.01 | 0.79 | 0.78 | 0.93 | 1.02 | 0.91 | 0.92 |
Average Inventory |
1.80 | 1.95 | 2.16 | 2.50 | 3.03 | 2.81 | 2.24 | 2.22 | 1.93 | 1.60 |
Average Assets |
5.37 | 5.12 | 5.23 | 11.25 | 14.54 | 11.60 | 12.91 | 11.85 | 7.60 | 6.35 |
Average Common Equity |
4.85 | 4.41 | 4.15 | 9.08 | 11.71 | 8.78 | 10.02 | 9.16 | 5.35 | 3.37 |
Columns are period end dates